Cisplatin protects against acute liver failure by inhibiting nuclear HMGB1 release

International Journal of Molecular Sciences

Volumn 14, Issue 6, 2013, Pages 11224-11237

  Li, Xun ^a   Wang, Li Kun ^a   Wang, Lu Wen ^a   Han, Xiao Qun ^a   Yang, Fan ^a   Gong, Zuo Jiong ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Acute liver failure; Cisplatin; High mobility group box 1; HMGB1 translocation; Inflammation

Indexed keywords

ALANINE AMINOTRANSFERASE; CISPLATIN; GAMMA INTERFERON; HIGH MOBILITY GROUP B1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ACUTE LIVER FAILURE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL LEVEL; CELL NUCLEUS; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOPLASM; DRUG EFFECT; ENZYME INHIBITION; ENZYME RELEASE; EXTRACELLULAR SPACE; GENE TRANSLOCATION; HEPATITIS; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER INJURY; LIVER PROTECTION; LOW DRUG DOSE; MACROPHAGE; MALE; NONHUMAN; RAT; SURVIVAL TIME; ANIMAL; BIOSYNTHESIS; BLOOD; CELL LINE; CELL PROTECTION; CELL SURVIVAL; DRUG EFFECTS; ENZYMOLOGY; LIVER FAILURE, ACUTE; METABOLISM; PATHOLOGY; SURVIVAL; TIME; WISTAR RAT;

RATTUS;

ALANINE TRANSAMINASE; ANIMALS; APOPTOSIS; CELL LINE; CELL NUCLEUS; CELL SURVIVAL; CISPLATIN; CYTOKINES; CYTOPROTECTION; HMGB1 PROTEIN; LIVER FAILURE, ACUTE; MACROPHAGES; MALE; RATS, WISTAR; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 84878455218     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms140611224     Document Type: Article

References (33)

1. Lotze, M.T.; Tracey, K.J. High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 2005, 5, 331-342.
2. Zhang, C.C.; Krieg, S.; Shapiro, D.J. HMG-1 stimulates estrogen response element binding by estrogen receptor from stably transfected HeLa cells. Mol. Endocrinol. 1999, 13, 632-643.
3. Bustin, M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol. Cell. Biol. 1999, 19, 5237-5246.
4. Yasuda, T.; Ueda, T.; Shinzeki, M.; Sawa, H.; Nakajima, T.; Takeyama, Y.; Kuroda, Y. Increase of high-mobility group box chromosomal protein 1 in blood and injured organs in experimental severe acute pancreatitis. Pancreas 2007, 34, 487-488.
5. Ueno, H.; Matsuda, T.; Hashimoto, S.; Amaya, F.; Kitamura, Y.; Tanaka, M.; Kobayashi, A.; Maruyama, I.; Yamada, S.; Hasegawa, N.; et al. Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am. J. Respir. Crit. Care Med. 2004, 170, 1310-1316.
6. Hamada, T.; Torikai, M.; Kuwazuru, A.; Tanaka, M.; Horai, N.; Fukuda, T.; Yamada, S.; Nagayama, S.; Hashiguchi, K.; Sunahara, N.; et al. Extracellular high mobility group box chromosomal protein 1 is a coupling factor for hypoxia and inflammation in arthritis. Arthritis Rheum. 2008, 58, 2675-2685.
7. Fan, J.; Li, Y.; Levy, R.M.; Hackam, D.J.; Vodovotz, Y.; Yang, H.; Tracey, K.J.; Billiar, T.R.; Wilson, M.A. Hemorrhagic shock induces NAD(P)H oxidase activation in neutrophils: Role of HMGB1-TLR4 signaling. J. Immunol. 2007, 178, 6573-6580.
8. Tsung, A.; Sahai, R.; Tanaka, H.; Nakao, A.; Fink, M.P.; Lotze, M.T.; Yang, H.; Li, J.; Tracey, K.J.; Geller, D.A.; et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J. Exp. Med. 2005, 201, 1135-1143.
9. Rabik, C.A.; Dolan, M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007, 33, 9-23.
10. Jamieson, E.R.; Lippard, S.J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev. 1999, 99, 2467-2498.
11. Woźniak, K.; Błasiak, J. Recognition and repair of DNA-cisplatin adducts. Acta Biochim. Pol. 2002, 49, 583-596.
12. Chauhan, P.; Sodhi, A.; Shrivastava, A. Cisplatin primes murine peritoneal macrophages for enhanced expression of nitric oxide, proinflammatory cytokines, TLRs, transcription factors and activation of MAP kinases upon co-incubation with L929 cells. Immunobiology 2009, 214, 197-209.
13. Pan, P.; Cardinal, J.; Dhupar, R.; Rosengart, M.R.; Lotze, M.T.; Geller, D.A.; Billiar, T.R.; Tsung, A. Low-dose cisplatin administration in murine cecal ligation and puncture prevents the systemic release of HMGB1 and attenuates lethality. J. Leukoc. Biol. 2009, 86, 625-632.
14. Park, S.; Lippard, S.J. Redox state-dependent interaction of HMGB1 and cisplatin-modified DNA. Biochemistry 2011, 50, 2567-2574.
15. Cardinal, J.; Pan, P.; Dhupar, R.; Ross, M.; Nakao, A.; Lotze, M.; Billiar, T.; Geller, D.; Tsung, A. Cisplatin prevents high mobility group box 1 release and is protective in a murine model of hepatic ischemia/reperfusion injury. Hepatology 2009, 50, 565-574.
16. Sozinov, A.S. Systemic endotoxemia during chronic viral hepatitis. Bull. Exp. Biol. Med. 2002, 133, 153-155.
17. Beutler, B.; Rietschel, E.T. Innate immune sensing and its roots: The story of endotoxin. Nat. Rev. Immunol. 2003, 3, 169-176.
18. Akira, S.; Uematsu, S.; Takeuchi, O. Pathogen recognition and innate immunity. Cell 2006, 124, 783-801.
19. Del Bufalo, A.; Bernad, J.; Dardenne, C.; Verda, D.; Meunier, J.R.; Rousset, F.; Martinozzi-Teissier, S.; Pipy, B. Contact sensitizers modulate the arachidonic acid metabolism of PMA-differentiated U-937 monocytic cells activated by LPS. Toxicol. Appl. Pharmacol. 2011, 256, 35-43.
20. Siddik, Z.H. Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22, 7265-7279.
21. Yan, S.; Ding, Y.; Sun, F.; Lu, Z.; Xue, L.; Liu, X.; Shuai, M.; Fang, C.; Wang, Y.; Cheng, H.; et al. Pretreatment of cisplatin in recipients attenuates post-transplantation pancreatitis in murine model. Int. J. Biol. Sci. 2012, 8, 298-309.
22. Yang, H.; Ochani, M.; Li, J.; Qiang, X.; Tanovic, M.; Harris, H.E.; Susarla, S.M.; Ulloa, L.; Wang, H.; DiRaimo, R.; et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. USA 2004, 101, 296-301.
23. Wang, H.; Bloom, O.; Zhang, M.; Vishnubhakat, J.M.; Ombrellino, M.; Che, J.; Frazier, A.; Yang, H.; Ivanova, S.; Borovikova, L.; et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285, 248-251.
24. Rendon-Mitchell, B.; Ochani, M.; Li, J.; Han, J.; Wang, H.; Yang, H.; Susarla, S.; Czura, C.; Mitchell, R.A.; Chen, G.; et al. IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J. Immunol. 2003, 170, 3890-3897.
25. Gardella, S.; Andrei, C.; Ferrera, D.; Lotti, L.V.; Torrisi, M.R.; Bianchi, M.E.; Rubartelli, A. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep. 2002, 3, 995-1001.
26. Bonaldi, T.; Talamo, F.; Scaffidi, P.; Ferrera, D.; Porto, A.; Bachi, A.; Rubartelli, A.; Agresti, A.; Bianchi, M.E. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 2003, 22, 5551-5560.
27. Liu, S.; Stolz, D.B.; Sappington, P.L.; Macias, C.A.; Killeen, M.E.; Tenhunen, J.J.; Delude, R.L.; Fink, M.P. HMGB1 is secreted by immunostimulated enterocytes and contributes to cytomix-induced hyperpermeability of Caco-2 monolayers. Am. J. Physiol. Cell Physiol. 2006, 290, C990-C999.
28. Scaffidi, P.; Misteli, T.; Bianchi, M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418, 191-195.
29. Yang, H.; Wang, H.; Czura, C.J.; Tracey, K.J. The cytokine activity of HMGB1. J. Leukoc. Biol. 2005, 78, 1-8.
30. Wang, H.; Yang, H.; Czura, C.J.; Sama, A.E.;Tracey, K.J. HMGB1 as a late mediator of lethal systemic inflammation. Am. J. Respir. Crit. Care Med. 2001, 164, 1768-1773.
31. Lu, Y.C.; Yeh, W.C.; Ohashi, P.S. LPS/TLR4 signal transduction pathway. Cytokine 2008, 42, 145-151.
32. Yang, H.; Tracey, K.J. Targeting HMGB1 in inflammation. Biochim. Biophys. Acta 2010, 1799, 149-156.
33. Zhang, C.X.; Chang, P.V.; Lippard, S.J. Identification of nuclear proteins that interact with platinum-modified DNA by photoaffinity labeling. J. Am. Chem. Soc. 2004, 126, 6536-6537.